Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Caicun Zhou, Chunxia Su et al.|The Lancet Respiratory Medicine|2021Cited by 183